NASDAQ:NITE - Nightstar Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$25.50 +0.02 (+0.08 %)
(As of 05/22/2019 04:00 PM ET)
Previous Close$25.48
Today's Range$25.46 - $25.50
52-Week Range$9.59 - $29.55
Volume2,542 shs
Average Volume303,029 shs
Market Capitalization$716.55 million
P/E RatioN/A
Dividend YieldN/A
Beta3.24
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.

Receive NITE News and Ratings via Email

Sign-up to receive the latest news and ratings for NITE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NITE
CUSIPN/A
Phone44-20-7611-2077

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.33 per share

Profitability

Net Income$-36,860,000.00

Miscellaneous

Employees47
Market Cap$716.55 million
Next Earnings Date8/12/2019 (Estimated)
OptionableNot Optionable

Nightstar Therapeutics (NASDAQ:NITE) Frequently Asked Questions

What is Nightstar Therapeutics' stock symbol?

Nightstar Therapeutics trades on the NASDAQ under the ticker symbol "NITE."

How were Nightstar Therapeutics' earnings last quarter?

Nightstar Therapeutics PLC (NASDAQ:NITE) posted its quarterly earnings results on Friday, May, 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.14. View Nightstar Therapeutics' Earnings History.

When is Nightstar Therapeutics' next earnings date?

Nightstar Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August 12th 2019. View Earnings Estimates for Nightstar Therapeutics.

What price target have analysts set for NITE?

10 equities research analysts have issued twelve-month target prices for Nightstar Therapeutics' shares. Their forecasts range from $25.18 to $40.00. On average, they anticipate Nightstar Therapeutics' share price to reach $28.3680 in the next year. This suggests a possible upside of 11.2% from the stock's current price. View Analyst Price Targets for Nightstar Therapeutics.

What is the consensus analysts' recommendation for Nightstar Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nightstar Therapeutics in the last year. There are currently 8 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nightstar Therapeutics.

What are Wall Street analysts saying about Nightstar Therapeutics stock?

Here are some recent quotes from research analysts about Nightstar Therapeutics stock:
  • 1. According to Zacks Investment Research, "Nightstar Therapeutics Limited is a clinical-stage gene therapy company. It focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy. The company operates primarily in North America and Europe. Nightstar Therapeutics Limited is based in LONDON, United Kingdom. " (5/7/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and $42/share price target on Nightstar Therapeutics. This morning, Spark (N) announced a definitive agreement to be acquired by Roche (RHHBY, NC) for $4.8 billion, or $114.50/share (a 122% premium). While we believe the primary driver of the acquisition was Spark’s hemophilia A program, we have observed a trend in late- stage gene therapy company acquisitions. Given that Nightstar is one of the furthest along with a Phase 3 trial reading out next year, we believe the company deserves a seat at the table for acquisition talks and interest from pharma." (2/26/2019)
  • 3. Mizuho analysts commented, "We attended Nightstar’s R&D Day yesterday where management presented preliminary data from the dose escalation study of NSR-RPGR for the treatment of X-Linked Retinitis Pigmentosa. We were encouraged by early signals observed in all cohort 3 patients and 2/6 patients in cohorts 4 and 5. However, the therapeutic dose to be taken into the upcoming expansion study remains to be determined as higher dose responders required a second course of steroids to control mild sub-retinal inflammation. The next important catalyst for the shares will be 2Q19 with six-months follow-up data from the dose escalation study. We maintain our Buy rating on the stock." (9/25/2018)

Has Nightstar Therapeutics been receiving favorable news coverage?

Media coverage about NITE stock has trended negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Nightstar Therapeutics earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future.

Who are some of Nightstar Therapeutics' key competitors?

What other stocks do shareholders of Nightstar Therapeutics own?

Who are Nightstar Therapeutics' key executives?

Nightstar Therapeutics' management team includes the folowing people:
  • Mr. David Fellows, CEO & Director (Age 62)
  • Mr. Senthil Vel Sundaram, Chief Financial Officer (Age 41)
  • Dr. Gregory Scott Robinson, Chief Scientific Officer (Age 60)
  • Brian Luque, Sr. Mang. of Investor Relations
  • Mr. Seokho Bryan Yoon Esq., Gen. Counsel & Sec. (Age 40)

When did Nightstar Therapeutics IPO?

(NITE) raised $76 million in an IPO on Thursday, September 28th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.

Who are Nightstar Therapeutics' major shareholders?

Nightstar Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include NEA Management Company LLC (4.32%), Gabelli Funds LLC (2.53%), Alpine Associates Management Inc. (2.19%), Water Island Capital LLC (1.75%), Water Island Capital LLC (1.75%) and GABELLI & Co INVESTMENT ADVISERS INC. (1.04%). Company insiders that own Nightstar Therapeutics stock include David A Fellows, Gregory Scott Robinson, Senthil Vel Sundaram and Tuyen Ong. View Institutional Ownership Trends for Nightstar Therapeutics.

Which institutional investors are selling Nightstar Therapeutics stock?

NITE stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley and JPMorgan Chase & Co.. Company insiders that have sold Nightstar Therapeutics company stock in the last year include David A Fellows, Gregory Scott Robinson, Senthil Vel Sundaram and Tuyen Ong. View Insider Buying and Selling for Nightstar Therapeutics.

Which institutional investors are buying Nightstar Therapeutics stock?

NITE stock was purchased by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, Alpine Associates Management Inc., NEA Management Company LLC, Water Island Capital LLC, Water Island Capital LLC, GABELLI & Co INVESTMENT ADVISERS INC., Citigroup Inc. and Goldman Sachs Group Inc.. View Insider Buying and Selling for Nightstar Therapeutics.

How do I buy shares of Nightstar Therapeutics?

Shares of NITE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nightstar Therapeutics' stock price today?

One share of NITE stock can currently be purchased for approximately $25.50.

How big of a company is Nightstar Therapeutics?

Nightstar Therapeutics has a market capitalization of $716.55 million. The company earns $-36,860,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Nightstar Therapeutics employs 47 workers across the globe.

What is Nightstar Therapeutics' official website?

The official website for Nightstar Therapeutics is http://www.nightstartx.com/.

How can I contact Nightstar Therapeutics?

Nightstar Therapeutics' mailing address is 215 EUSTON ROAD, LONDON X0, NW1 2BE. The company can be reached via phone at 44-20-7611-2077 or via email at [email protected]


MarketBeat Community Rating for Nightstar Therapeutics (NASDAQ NITE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  185 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  344
MarketBeat's community ratings are surveys of what our community members think about Nightstar Therapeutics and other stocks. Vote "Outperform" if you believe NITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NITE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/22/2019 by MarketBeat.com Staff

Featured Article: Treasury Bonds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel